Vijay Shah, MD, discusses phase 2 data showing zalfermin, cagrilintide, and semaglutide improved fibrosis biomarkers in alcohol-related liver disease.
Vijay Shah, MD
Advertisement
Vijay Shah, MD, is a consultant in the Division of Gastroenterology and Hepatology at Mayo Clinic in Rochester, Minnesota.
Articles by Vijay Shah, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
AHA 2026: Intensive Blood Pressure Control Reduces Events After Ischemic Stroke
2
STREAM: Statin Discontinuation Noninferior in Older Adults Without CVD
3
Common Diuretic Linked to Home Blood Pressure Lowering After Stroke
4
Bepirovirsen Functional Cure Durable Through Week 96 in Chronic Hepatitis B
5